PriceTargets.com logo

Hua Medicine (Shanghai) - HUMDF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.41 As of 11/28/2025 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for HUMDF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hua Medicine (Shanghai) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUMDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUMDF

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Hua Medicine (Shanghai) in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.41.

This chart shows the closing price for HUMDF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Hua Medicine (Shanghai). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2022Jefferies Financial GroupUpgradeHold ➝ Buy$8.00 ➝ $3.50
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease; and Fructokinase Inhibitor for Metabolic disease. The company was incorporated in 2011 and is based in Beijing, China.
Read More

Today's Range

Now: C$0.41
Low: C$0.41
High: C$0.41

50 Day Range

MA: C$0.41
Low: C$0.41
High: C$0.41

52 Week Range

Now: C$0.41
Low: C$0.15
High: C$0.41

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hua Medicine (Shanghai)?

The following Wall Street analysts have issued research reports on Hua Medicine (Shanghai) in the last twelve months:
View the latest analyst ratings for HUMDF.

What is the current price target for Hua Medicine (Shanghai)?

0 Wall Street analysts have set twelve-month price targets for Hua Medicine (Shanghai) in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Hua Medicine (Shanghai) in the next year.
View the latest price targets for HUMDF.

What is the current consensus analyst rating for Hua Medicine (Shanghai)?

Hua Medicine (Shanghai) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HUMDF.

What other companies compete with Hua Medicine (Shanghai)?

Other companies that are similar to Hua Medicine (Shanghai) include 1933 Industries, 4Cable TV International, 4Front Ventures, AB Science and Abacus Health Products. Learn More about companies similar to Hua Medicine (Shanghai).